ISDA

Entry Detail

PDB ID:

7NQ0

Keywords:

Title:

C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH oxabicyclo(hexan-6-yl)-N2-methyl-6-((S)-1-phenylethyl)pyridine-2,4-dicarboxamide

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2021-02-28

Release Date:

2021-07-21

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.30 Å

R-Value Free:

0.19

R-Value Work:

0.17

Space Group:

P 21 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Bromodomain-containing protein 2
Chain IDs:A (auth: AAA)
Chain Length:115
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P25440 Pfam ID:PF00439

Ligand Molecules

EDO

PE4

ULN

Primary Citation

Identification of a Series of N -Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

Harrison, L.A, Atkinson, S.J, Bassil, A, Chung, C.W, Grandi, P, Gray, J.R.J, Levernier, E, Lewis, A, Lugo, D, Messenger, C, Michon, A.M, Mitchell, D.J, Preston, A, Prinjha, R.K, Rioja, I, Seal, J.T, Taylor, S, Wall, I.D, Watson, R.J, Woolven, J.M, Demont, E.H.Show

J.Med.Chem. 64 10742 10771 (2021)

PMID: 34232650 DOI: 10.1021/acs.jmedchem.0c02155

Abstact

Domain-specific BET bromodomain ligands represent an attractive target for drug discovery with the potential to unlock the therapeutic benefits of antagonizing these proteins without eliciting the toxicological aspects seen with pan-BET inhibitors. While we have reported several distinct classes of BD2 selective compounds, namely, GSK620, GSK549, and GSK046, only GSK046 shows high aqueous solubility. Herein, we describe the lead optimization of a further class of highly soluble compounds based upon a picolinamide chemotype. Focusing on achieving >1000-fold selectivity for BD2 over BD1 ,while retaining favorable physical chemical properties, compound 36 was identified as being 2000-fold selective for BD2 over BD1 (Brd4 data) with >1 mg/mL solubility in FaSSIF media. 36 represents a valuable new in vivo ready molecule for the exploration of the BD2 phenotype.

Legend

Protein

Chemical

Disease

Primary Citation of related structures